Business
Kynexis Raises €97M to Chase a Hard Target: The Cognitive Symptoms of Schizophrenia
The Dutch biotech will push its brain-signaling drug through a mid-stage trial for cognitive impairment in schizophrenia — a common, disabling problem with no approved treatment.